Trillium Therapeutics, Inc., a Toronto, Canada-based biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, has raised $1m from a new undisclosed investor.
The company intends to use the funds to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis (IC), also known as bladder pain syndrome, and the prevention of necrotizing enterocolitis (NEC). The first trial is expected to start later this year.
Led by Dr. Niclas Stiernholm, CEO, and Dr. Bob Uger, Vice President R&D, Trillium plans to secure additional financing and/or a development partner prior to the start of randomized phase II studies in 2012.
The company also has a broad portfolio of preclinical immunology programs, including two programs for the treatment of cancer and autoimmune and inflammatory diseases.
Trillium previously raised funding from Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.